



# Pharmaids Pharmaceuticals Limited

Date: 30-10-2024

To  
The Manager  
Corporate Relations Department  
BSE Limited  
Phiroze Jeejeebhoy Towers, Dalal Street  
Mumbai – 400001

Dear Sir/Madam,

**BSE Scrip: PHARMAID | Code: 524572 | ISIN: INE117D01018**

**Sub: Pursuant to the requirement under regulation 30 of SEBI (Listing Obligation and Disclosure requirements) Regulation 2015 (“SEBI (LODR) Regulations, 2015”) – Intimation of acquisition of further stake in the Anugraha Chemicals (“the Firm”).**

**Ref: Outcome of the Board Meeting held on 17<sup>th</sup> January 2023 & 12<sup>th</sup> February 2024**

This is in furtherance to our intimations and intimation dated February 12, 2024 regarding further investment of up to an additional sum of Rs.16,50,00,000/- (Rupees Sixteen Crore Fifty Lakh Only) to acquire partnership interest up to 83% in Anugraha Chemicals and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you that following events had occurred today in the Company i.e. October 30, 2024 :-

1. The Company has acquired an additional stake in Anugraha Chemicals (“Partnership Firm”).
2. Execution of Interim Reconstitution of Partnership Deed dated 30.10.2024 with existing partners of the Firm.

The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are given in the enclosed **Annexure I**.

This is for your kind information and record.

Thanking you,

**For Pharmaids Pharmaceuticals Limited**

**Prasanna Subramanya Bhat**  
(Company Secretary & Compliance Officer)



## ANNEXURE 1

### ACQUISITION OF FURTHER STAKE IN ANUGRAHA CHEMICALS, A PARTNERSHIP FIRM, FROM EXISTING PARTNER 1 OF THE FIRM:

Name of the target entity, details in brief such as size, turnover etc.;	Anugraha Chemicals, a Partnership Firm, registered under the Karnataka Partnership (Registration of Firms), Rules, 1954, is having capital of Rs. 10,00,000/- (Rupees Ten Lakh Only) and turnover of Rs. 11,75,17,577/- (Rupees Eleven Crore Seventy-Five Lakhs Seventeen Thousand Five Hundred and Seventy Seven) as per the Audited Financial Statement for the Financial Year 2023-24.
Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of Interest and details thereof and whether the same is done at “arm’s length”.	<p>Yes, acquisition would fall within related party transactions and necessary approvals have been obtained.</p> <p>The firm is Jointly controlled by the Company along with its existing partners. Hence the firm is Related Party.</p> <p>The promoter/promoter group/group companies don’t have any interest in the entity being acquired. The transaction is done at arm’s length.</p>
Industry to which the entity being acquired belongs;	Anugraha Chemicals is engaged in Contract Manufacturing and Manufacturing of APIs, Intermediates and Fine Chemicals.
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisitions of target entity, if its business is outside the main line of business of the listed entity);	The business of the firm is in line with the business of the Company. This will help the company to achieve its objective of GMP Manufacturing. On the other hand, it will help the Firm to reach out the larger market and acquire large customer base.
Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
Indicative time period for completion of the acquisition	The acquisition and investment will be in multiple tranches as outlined in the Investment Agreement.
Nature of consideration – whether cash consideration or share swap and details of the same;	Cash consideration
Cost of acquisition or the price at which the shares are acquired;	Rs. 8,08,54,000 (Rupees Eight Crore Eight Lakh Fifty-Four Thousand) till date.



# Pharmaids Pharmaceuticals Limited

<p>Percentage of shareholding/control acquired and/or number of shares acquired;</p>	<p>After acquisition of further stake from Existing Partner 1, the Company's stake in firm will increase from 55.10% to 65.11%.</p> <p>As on October 30, 2024, the partnership firm has been restructured as mentioned below:</p> <table border="1" data-bbox="794 510 1412 712"> <thead> <tr> <th>Partners Name</th> <th>% interest</th> </tr> </thead> <tbody> <tr> <td>Pharmaids Pharmaceuticals Limited</td> <td>65.11</td> </tr> <tr> <td>Existing Partner 1</td> <td>1.39</td> </tr> <tr> <td>Existing Partner 2</td> <td>33.50</td> </tr> </tbody> </table>	Partners Name	% interest	Pharmaids Pharmaceuticals Limited	65.11	Existing Partner 1	1.39	Existing Partner 2	33.50				
Partners Name	% interest												
Pharmaids Pharmaceuticals Limited	65.11												
Existing Partner 1	1.39												
Existing Partner 2	33.50												
<p>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)</p>	<p>Anugraha Chemicals, a Partnership Firm, registered under the Karnataka Partnership (Registration of firms), Rules, 1954, was established in 1991 and has a rich experience of over two and half decades in the pharmaceutical industry. Anugraha Chemicals are engaged in Contract Manufacturing and Manufacturing of APIs, Intermediaries and Fine Chemicals.</p> <p>Turnover and net profits/loss of Anugraha Chemicals for the last three financial years are as follows:</p> <table border="1" data-bbox="794 1249 1412 1451"> <thead> <tr> <th>Financial Year</th> <th>Net Profit (In Rs.)</th> <th>Turnover (In Rs.)</th> </tr> </thead> <tbody> <tr> <td>2023-24</td> <td>(4,23,81,660)</td> <td>11,75,17,577</td> </tr> <tr> <td>2022-23</td> <td>13,64,544</td> <td>11,37,37,272</td> </tr> <tr> <td>2021-22</td> <td>12,71,130</td> <td>12,42,40,352</td> </tr> </tbody> </table>	Financial Year	Net Profit (In Rs.)	Turnover (In Rs.)	2023-24	(4,23,81,660)	11,75,17,577	2022-23	13,64,544	11,37,37,272	2021-22	12,71,130	12,42,40,352
Financial Year	Net Profit (In Rs.)	Turnover (In Rs.)											
2023-24	(4,23,81,660)	11,75,17,577											
2022-23	13,64,544	11,37,37,272											
2021-22	12,71,130	12,42,40,352											

**For Pharmaids Pharmaceuticals Limited**

**Prasanna Subramanya Bhat**  
**(Company Secretary & Compliance Officer)**